Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.

Brian T BurgessAbigail M AndersonJ Robert McCorkleJianrong WuFrederick Rand Ueland Jill M Kolesar

Published in: Diagnostics (Basel, Switzerland) (2020)

Combining an ATRi or Chk1i with olaparib is synergistic in both PARPi-sensitive and -resistant BRCA1 mutated OC cell models, and are rationale combinations for further clinical development.

Keyphrases

dna damage response
induced apoptosis
cell cycle arrest
single cell
wild type
cell therapy
breast cancer risk
cancer therapy
oxidative stress
dna repair
drug delivery
combination therapy
cell proliferation
mesenchymal stem cells